share_log

海创药业(688302.SH):HP568片用于治疗ER+/HER2-晚期乳腺癌临床试验申请获美国FDA批准

Hai Chuang Pharmaceutical (688302.SH): The clinical trial application for HP568 tablets for the treatment of ER+/HER2- advanced breast cancer has been approved by the USA FDA.

Zhitong Finance ·  Dec 30, 2024 15:39

Haichuang Pharmaceutical (688302.SH) announced that the company has received approval from the USA Food and Drug Administration (referred to as "FDA"...)

According to the Zhitong Finance APP, Haichuang Pharmaceutical (688302.SH) announced that the company has received a continuation notice for clinical research from the USA Food and Drug Administration (referred to as "FDA"). The clinical trial application for HP568 tablets, independently developed by the company for the treatment of estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer (ER+/HER2- advanced breast cancer), has been officially approved by the FDA. Previously, the clinical trial application for HP568 tablets for the same indication in China was approved by the National Medical Products Administration of China in October 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment